Can a Macrophage-Targeting drug supercharge CAR-T therapy?
NCT ID NCT07638982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer more effectively. The study enrolls adults with certain aggressive lymphomas who are eligible for CAR-T therapy and aims to find the safest and most effective dose of axatilimab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axatilimab
- What this could lead to
- If successful, this combination could improve the effectiveness of CAR-T therapy for people with hard-to-treat lymphomas.
- What could go wrong
- This is an early-phase trial with a small number of participants. The drug may not improve outcomes and could cause additional side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northside Hospital
Atlanta, Georgia, 30342, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment